PMI U.S. Calls for Science‑Based Policy and Credible, Open Dialogue to Accelerate America's Smoke‑Free Future

Rhea-AI Summary

Philip Morris International (NYSE:PM) U.S. businesses urged science-based policy and open dialogue on April 17, 2026 to accelerate a smoke-free future. A PMI U.S.-commissioned survey found 73% of adult smokers wrongly believe all nicotine products carry equal risk. PMI highlighted a backlog of FDA smoke-free product reviews and said 25–30 million American adults continue smoking.

PMI U.S. reiterated calls for clearer FDA communication to clinicians, collaboration among stakeholders, and wider access to FDA-authorized smoke-free alternatives.

News Market Reaction – PM

+0.99%

1 alert

+0.99% News Effect

On the day this news was published, PM gained 0.99%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Risk misperception rate: 73% Adult smokers in U.S.: 25–30 million Adult consumers target: 25–30 million +1 more

4 metrics

Risk misperception rate 73% Adults who believe all tobacco and nicotine products carry same risk

Adult smokers in U.S. 25–30 million Adult Americans who continue to smoke, per "Forgotten Smoker" paper

Adult consumers target 25–30 million Legal-age consumers who smoke cigarettes that PMI U.S. aims to serve

U.S. employees More than 3,000 People employed by PMI U.S. businesses across America

Market Reality Check

Price: $165.89 Vol: Volume 3,387,988 vs 20-da...

normal vol

$165.89 Last Close

Volume Volume 3,387,988 vs 20-day average 4,640,497 (relative volume 0.73). normal

Technical Trading below 200-day MA of 165.17 at a price of 156.24, and 18.33% below the 52-week high.

Peers on Argus

PM slipped 0.6% with mixed peer moves: BTI down 1.16%, MO up 0.92%, RLX up 0.93%...

PM slipped 0.6% with mixed peer moves: BTI down 1.16%, MO up 0.92%, RLX up 0.93%, KO slightly positive and PG slightly negative, pointing to stock-specific rather than broad sector trading.

Historical Context

5 past events · Latest: Apr 15 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 15	Illicit trade study	Negative	-1.4%	KPMG-commissioned study showing high illicit cigarette share and tax losses.
Apr 15	Earnings webcast notice	Neutral	-1.4%	Announcement of Q1 2026 results webcast and smoke-free user metrics.
Apr 14	Forgotten Smoker paper	Neutral	-2.0%	White paper and survey urging renewed public-health focus on adult smokers.
Apr 13	Brand partnership	Positive	+1.4%	Principal partnership with Ferrari Hypersail highlighting innovation and branding.
Mar 31	Value Report 2025	Positive	+0.3%	Release of Value Report 2025 with smoke-free revenue growth and ESG metrics.

Pattern Detected

Recent news has focused on smoke-free transition, regulatory positioning, and ESG themes, with price mostly aligning directionally with the perceived tone of each release.

Recent Company History

Over the past few weeks, PM highlighted smoke-free growth and broader ESG positioning, including its Value Report 2025 on Mar 31 and a Ferrari Hypersail partnership on Apr 13, both stressing the rise of smoke-free revenues and users. Other releases, such as illicit-trade findings and the “Forgotten Smoker” white paper, underscored regulatory and public-health challenges. Today’s Washington-focused call for science-based policy and dialogue continues this pattern of advocacy around harm reduction and smoke-free adoption in the U.S.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-06

PM has an effective S-3ASR automatic shelf filed on 2026-02-06, allowing issuance of debt securities and warrants to purchase debt securities over time, with proceeds earmarked for general corporate purposes such as debt repayment, working capital, capital expenditures, investments, acquisitions, and security repurchases or redemptions.

Market Pulse Summary

This announcement emphasizes PMI U.S.’s push for science-based regulation and clearer communication ...

Analysis

This announcement emphasizes PMI U.S.’s push for science-based regulation and clearer communication about the risk continuum between combustible cigarettes and smoke-free alternatives. It echoes themes from the recent “Forgotten Smoker” white paper, again highlighting the 25–30 million American adults who continue to smoke and the reported 73% misperception about product risks. Investors may watch how regulatory dialogue, FDA review backlogs, and public understanding evolve alongside PMI’s broader smoke-free transition strategy.

Key Terms

combustible cigarettes, smoke-free alternatives, u.s. food and drug administration (fda), tobacco harm reduction, +1 more

5 terms

combustible cigarettes technical

"America's transition away from combustible cigarettes is being held back"

A combustible cigarette is a rolled tobacco product that is lit and burned so the user inhales smoke and its chemicals, like burning a small log to produce smoke. It matters to investors because these products face steady regulatory restrictions, taxes, health-related litigation and shifting consumer tastes that can sharply affect sales, profit margins and long-term market viability for companies involved in making, selling or regulating tobacco products.

smoke-free alternatives technical

"science-backed smoke-free alternatives represent a better choice"

Products that deliver nicotine or tobacco flavor without burning plant material, such as e-cigarettes, heated tobacco devices, and nicotine pouches. They matter to investors because they represent a shifting market away from traditional cigarettes; changes in consumer adoption, regulation, or health perceptions can quickly affect sales, legal risk, and company valuations, much like replacing an open flame with an electric appliance alters demand and safety considerations.

u.s. food and drug administration (fda) regulatory

"backlog of smoke-free product applications at the U.S. Food and Drug Administration (FDA)"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

tobacco harm reduction medical

"public and medical understanding of the science behind tobacco harm reduction is essential"

Tobacco harm reduction is a public health and commercial strategy that aims to lower the health risks associated with smoking by encouraging the use of lower-risk alternatives, safer products, or quitting tools rather than relying on traditional combustible cigarettes. It matters to investors because shifts toward safer products change consumer demand, regulatory treatment, litigation risk and long-term sales trends—similar to how safer car designs alter the market for different vehicle models.

white paper technical

"These themes are explored further in PMI U.S.'s "Forgotten Smoker" white paper"

A white paper is a detailed, authoritative report that explains a company's product, technology, strategy, or policy, often outlining how it works, the problem it solves, and the assumptions behind it. Think of it as a combination of a how-to guide and a business plan that gives investors the facts, reasoning and projected benefits so they can judge credibility, risks and whether the proposal fits their investment goals.

AI-generated analysis. Not financial advice.

WASHINGTON, April 17, 2026 /PRNewswire/ -- Philip Morris International's U.S. businesses (PMI U.S.) brought a pointed message to Washington this week: America's transition away from combustible cigarettes is being held back—not by a lack of science, but by a lack of urgency. The call comes on the heels of Technovation, PMI's global science and innovation summit held in Washington, D.C., where policymakers, scientists, business leaders, public health advocates and the media examined the persistent challenges of cigarette smoking and the urgent need for evidence-based solutions. Central to those discussions: new research in the U.S. showing that a fundamental misperception among American legal-age adult smokers is actively slowing progress.

The findings of a PMI U.S. commissioned nationwide survey conducted by Povaddo LLC underscore the challenge: Seventy-three percent believe all tobacco and nicotine products carry the same risk, a misconception that can discourage those who continue to smoke from exploring FDA-authorized smoke-free alternatives. While the majority of Americans want to see more done to reduce smoking-related harm, progress has stalled. PMI U.S. says these findings point to a credibility crisis in public discourse around smoking and harm reduction, one that is costing lives.

Members of the Congressional Tobacco Harm Reduction Caucus echoed this urgency at Technovation, emphasizing the need for public health regulation that keeps pace with science and innovation. "We owe it to the American people to have better health outcomes," one caucus panelist said, underscoring bipartisan support for policies that reflect the latest evidence—not outdated assumptions.

"The data are clear: When adults who smoke aren't aware that better options exist, they are more likely to keep smoking. For those who would otherwise continue using combustible cigarettes, science-backed smoke-free alternatives represent a better choice, and public health policy should support informed choice and responsible progress," said Stacey Kennedy, Chief Executive Officer of PMI U.S. "If we are serious about reducing the harm caused by smoking in the United States, we need policies and conversations rooted in science, not stigma."

At Technovation, PMI U.S. outlined several core positions: 

• Science-based, smoke-free alternatives represent a better choice for adults who would otherwise continue to smoke. 
• Despite recent progress, there remains a backlog of smoke-free product applications at the U.S. Food and Drug Administration (FDA). Adults who smoke deserve access to the science-based, smoke-free options still awaiting agency review. 
• Misperceptions about nicotine and the role of combustion in smoking-related disease impede progress. Public and medical understanding of the science behind tobacco harm reduction is essential—and long overdue.
• To accelerate progress, the FDA should clearly communicate, especially to medical professionals, what the science says about smoke-free products' relative risk profiles, so adults who smoke can make informed choices.
• Collaboration among government, public health experts, scientists, and industry is needed to accelerate America's transition away from cigarettes, while protecting youth and supporting informed adult choice. 

These themes are explored further in PMI U.S.'s "Forgotten Smoker" white paper, which examines the 25-30 million adult Americans who continue to smoke and highlights the need for better access to affordable, smoke-free options and more accurate information about the continuum of risk.

Videos from Technovation are available at: https://www.pmi.com/technovation2026presskit/.

PMI U.S.: Invested in America
Philip Morris International Inc.'s U.S. businesses are invested in America's future and advancing a smoke-free nation. The businesses are committed to providing the 25-30 million legal-age consumers who smoke cigarettes with better, smoke-free alternatives and to ensuring the products are marketed responsibly. From PMI's global headquarters in Stamford, Connecticut, and other locations nationwide, PMI U.S. contributes leadership, jobs, investment, and innovation in the U.S. The U.S. businesses employ more than 3,000 people across America and operate product manufacturing facilities, including in Owensboro, Kentucky, and Wilson, North Carolina. For more information, please visit www.uspmi.com.

References to "PMI" mean the Philip Morris International family of companies. "PMI U.S.," "we," "our," and "us" refer to one or more PMI U.S. businesses.

View original content to download multimedia:https://www.prnewswire.com/news-releases/pmi-us-calls-for-sciencebased-policy-and-credible-open-dialogue-to-accelerate-americas-smokefree-future-302745877.html

SOURCE PMI US Corporate Services, Inc.

FAQ

What did PMI U.S. announce at Technovation on April 17, 2026 (PM)?

PMI U.S. called for science-based policy and credible dialogue to advance a smoke-free future for adults who smoke. According to PMI U.S., the event highlighted a nationwide survey, FDA review backlogs, and the need to inform clinicians about relative risks.

What did the PMI U.S. survey find about U.S. adult smokers' risk perceptions (PM)?

The survey found that 73% of legal‑age adult smokers believe all tobacco and nicotine products carry the same risk. According to PMI U.S., that misperception may discourage smokers from considering FDA‑authorized smoke‑free alternatives.

How many Americans still smoke according to PMI U.S. (PM)?

PMI U.S. cites an estimated 25–30 million legal‑age Americans who continue to smoke cigarettes. According to PMI U.S., this 'forgotten smoker' group underscores the need for better access to affordable smoke‑free options and accurate risk information.

What policy changes did PMI U.S. urge the FDA to make (PM)?

PMI U.S. urged clearer FDA communication to medical professionals about smoke‑free products' relative risk profiles and faster review of pending applications. According to PMI U.S., better guidance would help informed choice for adults who smoke.

Where does PMI U.S. operate and how many U.S. employees are reported (PM)?

PMI U.S. reports more than 3,000 employees and manufacturing sites including Owensboro, Kentucky and Wilson, North Carolina. According to PMI U.S., operations from Stamford, Connecticut support leadership, jobs, investment, and innovation in the U.S.

Where can investors find videos and the PMI U.S. "Forgotten Smoker" white paper (PM)?

PMI U.S. made Technovation videos and the "Forgotten Smoker" white paper available online at the company's press kit and investor resources. According to PMI U.S., these materials explore survey findings and policy recommendations to reduce smoking harm.